Pazotev 200 & 400 200 mg, 400 mg FC TABLETS
PDF Leaflet Revision Date: 18 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of advanced and/or metastatic renal cell carcinoma.
Dosage (summary)
800 mg orally once daily; dose modifications in 200 mg increments based on tolerability.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; breastfeeding should be discontinued during treatment.
Key Drug Interactions
- Strong CYP3A4 inhibitors
- Simvastatin
- Grapefruit juice
Contraindications
- Hypersensitivity to pazopanib or excipients
Common side effects
- Hypertension
- Hypothyroidism
- Proteinuria
- Fatigue
- Diarrhoea
Counselling Points
- Take without food
- Monitor liver function
- Use contraception during treatment
- Report signs of liver dysfunction
Serious warnings
- Hepatic failure
- Hypertension
- PRES/RPLS
- Cardiac dysfunction
- GI perforations
Important Disclaimer
The Pazotev 200 & 400 200 mg, 400 mg FC TABLETS professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
